TRCT
PVLA

Tower Research Capital (TRC)’s Palvella Therapeutics PVLA Stock Holding History

Tower Research Capital (TRC)’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$134K Buy
1,076
+639
+146% +$66.7K ﹤0.01% 1946
2025
Q4 		$45.7K Sell
437
-12
-3% -$1.02K ﹤0.01% 2487
2025
Q3 		$28.1K Buy
449
+257
+134% +$11.5K ﹤0.01% 3004
2025
Q2 		$4.33K Buy
+192
New +$4.51K ﹤0.01% 4341
2025
Q1 		– Sell
-175
Closed -$2.1K – 5966
2024
Q4 		$2.1K Buy
+175
New +$2.75K ﹤0.01% 4905
2024
Q3 		– Sell
-334
Closed -$3.28K – 6054
2024
Q2 		$3.28K Sell
334
-200
-37% -$2.25K ﹤0.01% 4912
2024
Q1 		$7.82K Buy
534
+433
+429% +$6.03K ﹤0.01% 4128
2023
Q4 		$1.48K Sell
101
-285
-74% -$5.22K ﹤0.01% 5371
2023
Q3 		$9.21K Buy
386
+79
+26% +$1.7K ﹤0.01% 4244
2023
Q2 		$4.07K Buy
307
+137
+81% +$8.31K ﹤0.01% 4994
2023
Q1 		$13K Buy
170
+24
+16% +$2.78K ﹤0.01% 4024
2022
Q4 		$12K Sell
146
-124
-46% -$9.96K ﹤0.01% 3767
2022
Q3 		$25K Buy
270
+267
+8,900% +$34.4K ﹤0.01% 3775
2022
Q2 		$0 Sell
3
-7
-70% -$1.28K ﹤0.01% 6608
2022
Q1 		$3K Buy
10
+5
+100% +$1.31K ﹤0.01% 5438
2021
Q4 		$2K Buy
+5
New +$1.6K ﹤0.01% 5689
2021
Q3 		– Sell
-144
Closed -$50.1K – 6259
2021
Q2 		$44K Buy
144
+5
+4% +$1.1K ﹤0.01% 3134
2021
Q1 		$29K Sell
139
-64
-32% -$14K ﹤0.01% 3591
2020
Q4 		$41K Sell
203
-528
-72% -$110K ﹤0.01% 3311
2020
Q3 		$121K Buy
731
+600
+458% +$137K ﹤0.01% 3002
2020
Q2 		$32K Buy
+131
New +$30.6K ﹤0.01% 3406
2020
Q1 		– Sell
-28
Closed -$8K – 4050
2019
Q4 		$8K Buy
28
+14
+100% +$3.88K ﹤0.01% 2472
2019
Q3 		$4K Sell
14
-59
-81% -$22.8K ﹤0.01% 3473
2019
Q2 		$28K Buy
73
+67
+1,117% +$20K ﹤0.01% 1960
2019
Q1 		$2K Sell
6
-39
-87% -$9.27K ﹤0.01% 3476
2018
Q4 		$9K Buy
45
+24
+114% +$7.45K ﹤0.01% 2583
2018
Q3 		$9K Buy
+21
New +$9.13K ﹤0.01% 2845
2018
Q2 		– Sell
-2
Closed -$1K – 4132
2018
Q1 		$1K Buy
+2
New +$1.24K ﹤0.01% 3117
2017
Q4 		– Sell
-52
Closed -$24K – 4106
2017
Q3 		$24K Buy
+52
New +$22.2K ﹤0.01% 2628
2017
Q2 		– Sell
-3
Closed -$1K – 3559
2017
Q1 		$1K Buy
+3
New +$531 ﹤0.01% 2869
2016
Q4 		– Sell
-40
Closed -$4.95K – 4489
2016
Q3 		$6K Buy
40
+34
+567% +$4.52K ﹤0.01% 2455
2016
Q2 		$1K Sell
6
-6
-50% -$920 ﹤0.01% 4236
2016
Q1 		$2K Buy
+12
New +$1.69K ﹤0.01% 3461
2015
Q3 		– Sell
-6
Closed -$1K – 4897
2015
Q2 		$1K Buy
+6
New +$1.32K ﹤0.01% 4103

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Tower Research Capital (TRC)'s PVLA Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Palvella Therapeutics (PVLA) stake by 146% in Q1 2026, buying an estimated $66.7K and bringing the position to 1,076 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #1946.

Tower Research Capital (TRC) first reported a position in PVLA in Q2 2015 and has held it in 34 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Tower Research Capital (TRC) held 1,076 shares of Palvella Therapeutics worth $134K as of Q1 2026.
  • Tower Research Capital (TRC) bought 639 Palvella Therapeutics shares in Q1 2026, an estimated $66.7K.
  • Palvella Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #1946 holding.
  • Tower Research Capital (TRC) first reported a position in Palvella Therapeutics in Q2 2015 and has held it in 34 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.